Genscript Biotech Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Genscript Biotech şirketinin kazançları yıllık ortalama -8.7% oranında azalırken, Life Sciences sektörünün kazançları yıllık 20.8% oranında artan oldu. Gelirler yıllık ortalama 26.5% oranında artan oldu.

Anahtar bilgiler

-8.7%

Kazanç büyüme oranı

-6.4%

EPS büyüme oranı

Life Sciences Sektör Büyümesi	41.4%
Gelir büyüme oranı	26.5%
Özkaynak getirisi	-17.8%
Net Marj	-17.5%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Genscript Biotech nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

SHSC:1548 Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	1,010	-177	424	462
31 Mar 24	925	-136	408	447
31 Dec 23	840	-95	393	433
30 Sep 23	773	-140	383	426
30 Jun 23	707	-185	374	420
31 Mar 23	667	-206	363	405
31 Dec 22	626	-227	352	390
30 Sep 22	598	-315	354	375
30 Jun 22	570	-403	356	361
31 Mar 22	530	-381	330	360
31 Dec 21	490	-359	303	358
30 Sep 21	483	-265	270	341
30 Jun 21	454	-183	235	323
31 Mar 21	422	-194	216	293
31 Dec 20	391	-205	197	263
30 Sep 20	354	-194	171	251
30 Jun 20	318	-183	146	239
31 Mar 20	296	-140	136	212
31 Dec 19	273	-97	126	186
30 Sep 19	257	-59	112	148
30 Jun 19	241	-22	98	109
31 Mar 19	236	0	89	92
31 Dec 18	231	21	79	74
30 Sep 18	216	24	72	58
30 Jun 18	201	27	65	41
31 Mar 18	177	26	56	30
31 Dec 17	153	26	47	18
30 Sep 17	139	27	48	11
30 Jun 17	125	28	49	5
31 Mar 17	120	27	50	2
31 Dec 16	115	26	51	0
30 Sep 16	107	26	50	0
30 Jun 16	99	25	48	0
31 Mar 16	93	21	47	0
31 Dec 15	87	18	46	0
30 Sep 15	82	13	43	0
30 Jun 15	78	8	39	0
31 Mar 15	74	7	38	0
31 Dec 14	70	6	37	0
31 Dec 13	60	6	29	0

Kaliteli Kazançlar: 1548 şu anda kârlı değil.

Büyüyen Kar Marjı: 1548 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 1548 kârlı değildir ve zararlar son 5 yılda yılda 8.7% oranında artmıştır.

Büyüme Hızlandırma: 1548 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 1548 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Life Sciences sektörüyle ( -3.9% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 1548 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -17.82% ) sahiptir.

Genscript Biotech Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First half 2024 earnings released: US$0.083 loss per share (vs US$0.044 loss in 1H 2023)

First half 2024 earnings released: US$0.083 loss per share (vs US$0.044 loss in 1H 2023)

Genscript Biotech Corporation to Report First Half, 2024 Results on Aug 09, 2024

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

Recent updates

Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group

Board Member recently sold HK$901k worth of stock

Now 21% overvalued after recent price rise

Genscript Biotech Corporation Announces Late-Breaking Long-Term Overall Survival Data from Cartitude-4 Study in Multiple Myeloma

Genscript Biotech Corporation Announces Board Appointments

First half 2024 earnings released: US$0.083 loss per share (vs US$0.044 loss in 1H 2023)

First half 2024 earnings released: US$0.083 loss per share (vs US$0.044 loss in 1H 2023)

Genscript Biotech Corporation to Report First Half, 2024 Results on Aug 09, 2024

New minor risk - Share price stability

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Now 25% undervalued after recent price drop

Insider recently sold HK$1.0m worth of stock

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

New minor risk - Profitability

Executive Chairman recently sold HK$610k worth of stock

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold HK$1.4m worth of stock

Full year 2022 earnings released: US$0.11 loss per share (vs US$0.17 loss in FY 2021)

Now 24% undervalued

Now 20% undervalued

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

Less than half of directors are independent

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Genscript Biotech Corporation Announces Board Changes

Genscript Biotech Corporation Announces Board Changes

Full year 2021 earnings released: US$0.17 loss per share (vs US$0.11 loss in FY 2020)

Less than half of directors are independent

Genscript Biotech Corporation, Annual General Meeting, May 27, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021

Board Member recently sold HK$2.1m worth of stock

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Key Executive recently sold HK$9.1m worth of stock

Duke-NUS Medical School and GenScript Biotech Corporation Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test

Hillhouse Capital Management, Ltd. completed the acquisition of 2.99% stake in Genscript Biotech Corporation (SEHK:1548) from GenScript Corporation.

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.052 loss in FY 2019)

Full year 2020 earnings released

Genscript Biotech Corporation to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: HK$14.66

Genscript Probio and Neoletix Announce Successful Completion of 200-Liter Gmp Production Runs of Recombinant Coagulation Fviii Based on A Novel Production Technology

New 90-day low: HK$10.18

New 90-day low: HK$10.36

Genscript Biotech Corporation Announces Board and Director Changes

New 90-day low: HK$11.38

Co-Founder recently bought HK$3.7m worth of stock

First half earnings released

New 90-day low: HK$11.48

First half earnings released

New 90-day low - HK$14.96

Genscript Biotech Corporation to Report Q2, 2020 Results on Aug 29, 2020

Genscript Biotech Corporation Announces Management Changes Effective 2 August 2020

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi